KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Liabilities (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Total Liabilities data on record, last reported at $2.2 billion in Q3 2025.

  • For Q3 2025, Total Liabilities fell 8.64% year-over-year to $2.2 billion; the TTM value through Sep 2025 reached $2.2 billion, down 8.64%, while the annual FY2024 figure was $2.4 billion, 1.26% up from the prior year.
  • Total Liabilities reached $2.2 billion in Q3 2025 per SRPT's latest filing, down from $2.3 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $2.7 billion in Q4 2022 and bottomed at $2.2 billion in Q3 2025.
  • Average Total Liabilities over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2025.
  • Peak YoY movement for Total Liabilities: grew 24.29% in 2022, then dropped 13.94% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $2.2 billion in 2021, then rose by 23.58% to $2.7 billion in 2022, then dropped by 12.33% to $2.4 billion in 2023, then increased by 1.26% to $2.4 billion in 2024, then fell by 10.76% to $2.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $2.2 billion in Q3 2025, $2.3 billion in Q2 2025, and $2.3 billion in Q1 2025.